RESUMEN
Currently, there is no single, Europe-wide regulation of biomedical research using human samples and data. Instead, the law that applies spans a number of areas of law, such as data protection, clinical trials, and tissue regulation. In the absence of harmonized regulation, there is considerable scope for national legal variation. This article analyzes the legislative frameworks that apply to biobanking activities to identify differences in legal requirements between the BioSHaRE-EU project countries: Finland, France, Germany, the Netherlands, Norway, and the United Kingdom. This article highlights the primary role of consent and accompanying governance mechanisms, such as research ethics committee oversight, which enable consent exemptions in the context of research. Our analysis identifies a complicated legal landscape, whereby broadly similar provisions are contained in varied sources of law in each jurisdiction. The challenge for researchers is locating the applicable legal provisions within each national legal framework.
Asunto(s)
Bancos de Muestras Biológicas/legislación & jurisprudencia , Investigación Biomédica/legislación & jurisprudencia , Comités de Ética en Investigación/legislación & jurisprudencia , Investigación Biomédica/organización & administración , Formularios de Consentimiento/organización & administración , Unión Europea/organización & administración , Finlandia , Francia , Alemania , Humanos , Países Bajos , Noruega , Reino UnidoRESUMEN
This paper discusses the nature of genomic information, and the moral arguments in support of an individual's right to access it. It analyses the legal avenues an individual might take to access their sequence information. The authors describe the policy implications in this area and conclude that, for now, the law appears to strike an appropriate balance, but new policy will need to be developed to address this issue.
Asunto(s)
Privacidad Genética/legislación & jurisprudencia , Investigación Genética/legislación & jurisprudencia , Pruebas Genéticas/legislación & jurisprudencia , Acceso de los Pacientes a los Registros/legislación & jurisprudencia , Bases de Datos Genéticas , Privacidad Genética/ética , Investigación Genética/ética , Pruebas Genéticas/ética , Genoma Humano , Humanos , Acceso de los Pacientes a los Registros/ética , Reino UnidoRESUMEN
Advances in computing technology and bioinformatics mean that medical research is increasingly characterized by large international consortia of researchers that are reliant on large data sets and biobanks. These trends raise a number of challenges for obtaining consent, protecting participant privacy concerns and maintaining public trust. Participant-centred initiatives (PCIs) use social media technologies to address these immediate concerns, but they also provide the basis for long-term interactive partnerships. Here, we give an overview of this rapidly moving field by providing an analysis of the different PCI approaches, as well as the benefits and challenges of implementing PCIs.
Asunto(s)
Investigación Biomédica/ética , Medios de Comunicación Sociales/ética , Biología Computacional/ética , Humanos , Consentimiento Informado/ética , PrivacidadRESUMEN
An increasing number of private companies are now offering direct-to-consumer (DTC) genetic testing services. Although a lot of attention has been devoted to the regulatory framework of DTC genetic testing services in the USA, only limited information about the regulatory framework in Europe is available. We will report on the situation with regard to the national legislation on DTC genetic testing in seven European countries (Belgium, the Netherlands, Switzerland, Portugal, France, Germany, the United Kingdom). The paper will address whether these countries have legislation that specifically address the issue of DTC genetic testing or have relevant laws that is pertinent to the regulatory control of these services in their countries. The findings show that France, Germany, Portugal and Switzerland have specific legislation that defines that genetic tests can only be carried out by a medical doctor after the provision of sufficient information concerning the nature, meaning and consequences of the genetic test and after the consent of the person concerned. In the Netherlands, some DTC genetic tests could fall under legislation that provides the Minister the right to refuse to provide a license to operate if a test is scientifically unsound, not in accordance with the professional medical practice standards or if the expected benefit is not in balance with the (potential) health risks. Belgium and the United Kingdom allow the provision of DTC genetic tests.
Asunto(s)
Asesoramiento Genético/legislación & jurisprudencia , Pruebas Genéticas/legislación & jurisprudencia , Política de Salud/legislación & jurisprudencia , Publicidad , Participación de la Comunidad/legislación & jurisprudencia , Europa (Continente) , Asesoramiento Genético/ética , Predisposición Genética a la Enfermedad/genética , Pruebas Genéticas/ética , Pruebas Genéticas/normas , Humanos , Consentimiento Informado , Factores de RiesgoRESUMEN
Consent forms are the principal method for obtaining informed consent from biomedical research participants. The significance of these forms is increasing as more secondary research is undertaken on existing research samples and information, and samples are deposited in biobanks accessible to many researchers. We reviewed a selection of consent forms used in European Genome-Wide Association Studies (GWAS) and identified four common elements that were found in every consent form. Our analysis showed that only two of the four most commonly found elements in our sample of informed consent forms were required in UK law. This raises questions about what should be put in informed consent forms for research participants. These findings could be beneficial for the formulation of participant information and consent documentation in the future studies.
Asunto(s)
Formularios de Consentimiento/legislación & jurisprudencia , Investigación Genética , Sujetos de Investigación , Ética en Investigación , Genómica , Humanos , Reino UnidoRESUMEN
Analyses of individuals' genomes--their entire DNA sequence--have increased knowledge about the links between genetics and disease. Anticipated advances in 'next generation' DNA-sequencing techniques will see the routine research use of whole genomes, rather than distinct parts, within the next few years. The scientific benefits of genomic research are, however, accompanied by legal and ethical concerns. Despite the assumption that genetic research data can and will be rendered anonymous, participants' identities can sometimes be elucidated, which could cause data protection legislation to apply. We undertake a timely reappraisal of these laws--particularly new penalties--and identifiability in genomic research.